Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824566 | 1.00 | CA2 (0.54) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| Hydrochloric Acid SCHEMBL15818713 | 0.98 | CA2 (0.53) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| SCHEMBL8359747 | 0.84 | MAOB (0.71) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| SCHEMBL30396397 | 0.83 | HTR1D (0.53) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| SCHEMBL140189 | 0.83 | HTR1D (0.53) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| Hydrochloric Acid SCHEMBL30297758 | 0.82 | HTR1D (0.51) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| Hydrochloric Acid SCHEMBL20542639 | 0.82 | HTR1D (0.51) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| SCHEMBL5237537 | 0.80 | CA2 (0.49) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| SCHEMBL6511946 | 0.80 | MAOB (0.71) | CA2MAOBCYP11B1CYP11B2CYP17A1 | |
| SCHEMBL5235143 | 0.79 | CA2 (0.47) | CA2MAOBCYP11B1CYP11B2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | CYTOKINETICS, INC. | 2024-02-29 | — | — | US | disclosed |
| EP-3546454-B1 | BENZOHETEROCYCLYL ALKYLAMINE COMPOUND AND USE THEREOF | UNIV EAST CHINA SCIENCE & TECH (CN) | 2023-09-27 | — | — | EP | disclosed |
| EP-3601224-B1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2023-07-05 | — | — | EP | disclosed |
| CN-110914238-B | Compounds as antibiotics | 安塔比奥公司 | 2023-06-20 | — | — | CN | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| WO-2021216998-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-11000511-B2 | Chemical compounds as antibiotics | ANTABIO SAS (FR) | 2021-05-11 | — | — | US | disclosed |
| EP-3765005-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | The Regents of the University of California (US) | 2021-01-20 | — | — | EP | disclosed |
| JP-2000007671-A | 2,3-DIHYDROBENZOFURAN DERIVATIVE | ASAHI CHEM IND CO LTD | 2000-01-11 | — | — | JP | disclosed |
| US-5807889-A | PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | H. LUNDBECK A/S (DK) | 1998-09-15 | — | — | US | disclosed |
| US-5792791-A | FOR PREVENTION AND TREATMENT OF SEROTONERGIC NEURON-RELATED DISEASES; HYPOTENSIVE AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-08-11 | — | — | US | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0259092-B1 | SUBSTITUTED HEXAHYDROARYLQUINOLIZINES | MERCK & CO. INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| US-4916223-A | ALPAH 2-ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1990-04-10 | — | — | US | disclosed |
| US-4831035-A | Substituted hexahydroarylquinolizines | MERCK & CO., INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0259092-A1 | Substituted hexahydroarylquinolizines | MERCK & CO. INC. (US) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | CA2 1117/4885MAOB 2880/4885CYP11B1 4469/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | CA2 1117/4885MAOB 2880/4885CYP11B1 4469/4885 |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | NAMPT, NNT, NAPRT | CA2 3380/4885MAOB 716/4885CYP11B1 251/4885 |
| US-11000511-B2 | Chemical compounds as antibiotics | MRPL21, CFTR, H1-0 | CA2 3287/4885MAOB 2404/4885CYP11B1 4604/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | CA2 3956/4885MAOB 4698/4885CYP11B1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.